Introduction
The rapid expansion of the dietary supplement industry has been accompanied by uneven regulation and inadequate quality control, creating persistent risks that products contain undeclared pharmacological adulterants, including substances prohibited by the World Anti-Doping Agency (WADA).[1] This contamination undermines sport credibility and places athletes at risk of unintentional anti-doping rule violations (ADRVs) with consequential suspensions and reputational harm, making the issue central to Olympic anti-doping policy and practice.[1, 2] The significance extends beyond elite sport because undeclared substances can expose consumers to unintended drug ingestion, and some of these substances may cause adverse health effects, with sales described as illegal under certain national enforcement contexts.[3]
In the Olympic anti-doping governance framework, strict liability connects product quality failures to legal and disciplinary outcomes for athletes.[4, 5] Under strict liability, an athlete is responsible for substances found in their doping control samples regardless of intention, and inadvertent doping scenarios explicitly include ingestion of adulterated or faked dietary supplements, among other exposure routes.[4] Because responsibility is triggered by analytical findings rather than intent, the most practical risk-reduction leverage point is prevention of undeclared substances entering supplements and robust verification that marketed products match their labels.[3, 4]
Multiple international studies have reported substantial prevalence of contamination in supplements intended for people who exercise and engage in sports, with the range reported as 12–58% containing substances prohibited by the World Anti-Doping Code (WADC).[3] Critically, in some cases the doping substances are not declared on product labels, leaving consumers unaware of what is ingested and making product selection based on labels alone unreliable for both athletes and non-athletes.[3] Widespread supplement use in sport amplifies the population-level consequences of a non-trivial contamination prevalence, with estimates suggesting nearly 60–80% of athletes consume supplements regularly and other summaries indicating 40–100% use depending on country, sport, and definitions used.[6, 7]
Anti-doping concerns have motivated targeted screening studies explicitly framed around substances banned by the International Olympic Committee and WADA, reinforcing that this is not a niche academic topic but a recurrent operational problem at the interface of sport governance and consumer markets.[5] Complementary commentary has linked inadvertent doping via nutritional supplements to increases in positive drug tests involving high-profile Olympic athletes, further positioning undeclared ingredients as a practical driver of sanction risk rather than a merely theoretical hazard.[5] In this context, the International Olympic Committee’s broader stake is not only competitive integrity but also the credibility of Olympic anti-doping systems when athletes face sanctions arising from consumer products sold through ordinary retail channels.[1, 2]
A key enabling condition for continued market entry of contaminated products is the regulatory treatment of supplements as distinct from medicines in major jurisdictions, resulting in weaker pre-market controls compared with drug regulation.[8, 9] In the United States, supplements are classified as a category of food and are not subject to the premarket safety and effectiveness testing required for drugs, with the Food and Drug Administration (FDA) relying largely on postmarket surveillance (including adverse event reports, complaints, inspections, and import screening) to identify unsafe or adulterated products.[8] This combination—high prevalence signals, frequent use by athletes, strict liability in Olympic anti-doping, and post-market regulatory posture—sets the stage for a persistent “crisis of undeclared substances” affecting both athlete careers and consumer safety.[1, 2, 8]
Evidence base in scope
The evidence synthesised in this review comprises (i) narrative syntheses reporting aggregate contamination prevalence and product-category patterns, (ii) empirical screening studies that quantify undeclared prohibited substances in sampled supplements, (iii) analytical methods papers describing chromatographic–mass spectrometric workflows and detection limits relevant to trace contamination, and (iv) regulatory and quality-assurance analyses describing structural constraints and mitigations (including GMP and third-party certification).[1, 8, 10–12]
The IOC and WADA Evidence Base
Across literature aligned with the International Olympic Committee’s concern for Olympic anti-doping integrity, contaminated supplements remain a measurable pathway to exposure to prohibited substances in the athlete population.[1, 2] Syntheses of empirical studies indicate that approximately 9–15% of commercially available supplements tested were contaminated with prohibited substances and unapproved pharmacological agents, with stimulants and anabolic agents commonly represented among the detected substances.[1] These data also suggest that contamination concentrates in specific consumer-facing product categories, with pre-workout, weight-loss, and muscle-building products most frequently identified as contaminated in reviewed empirical studies.[1]
A canonical prevalence anchor repeatedly discussed in this domain is the Geyer et al. analysis of “non-hormonal” supplements, which has become a reference point for anti-doping risk communication and subsequent replication efforts.[9] In one summary description, 94 of 634 analysed supplements (14.8%) contained prohormones not mentioned on the label, illustrating a large, quantifiable label–content discrepancy in products marketed as non-hormonal.[9] Related summaries emphasise that banned substances—including ephedrine, caffeine, steroids, and prohormones—were found in some “non-hormonal” nutritional supplements, underscoring that marketing descriptors are not reliable indicators of chemical composition from a WADA rule-compliance perspective.[13, 14]
Independent screening studies with smaller sample sizes nevertheless reinforce the same core message: undeclared prohibited substances can appear in retail supplements at rates sufficient to matter for Olympic anti-doping risk management.[5, 10] For example, in a method-based investigation applied to 64 nutritional supplements, 12.5% contained banned substances not declared on the label, specifically anabolic steroids and ephedrine, showing that prohibited stimulants and anabolic agents can co-occur as hidden ingredients in consumer products.[10] In another over-the-counter screening study of 30 supplements from 14 manufacturers, 12 of 30 (40%) were positive for prohibited compounds, with prohormones present in 8 of the 12 positive products (66.7%) and stimulants in 4 of 12 (33.3%).[5] Notably, within that same dataset, only 2 of 30 (6.7%) were explicitly described as “contaminated or mislabelled,” suggesting that, operationally, detection of prohibited compounds may not always be framed as contamination by authors even when undeclared substances are present and relevant to Olympic anti-doping outcomes.[5]
Evidence from online-market sampling indicates that contamination and adulteration risks are not confined to a single retail channel and may encompass doping agents, pharmaceuticals, and other illegal ingredient levels.[3] In a Norwegian analysis of 93 dietary supplements collected for laboratory testing, 21 of 93 (23%) contained doping agents, pharmaceutical drugs, and/or illegal amounts of caffeine, reflecting a mixed pattern of prohibited substances and broader pharmacological adulteration in products accessible to consumers.[3] Complementing individual studies, broader summaries report that contamination rates in ergonutritional supplements varied from 12% to 58% in samples analysed between 2002 and 2005, including instances where hormones were detected in products that should not have contained them, reinforcing that high contamination rates have been repeatedly documented rather than being a single-study anomaly.[9, 15]
The operational implications of these prevalence estimates are shaped by how WADA defines and updates prohibited categories, which can capture both explicitly listed agents and emerging analogues relevant to supplement adulteration.[16] The 2026 WADA Prohibited List defines categories such as anabolic agents (S1), hormone and metabolic modulators (S4), and stimulants (S6), and it also includes “catch-all” clauses for substances with similar chemical structures or biological effects, encompassing emerging structural analogues and unapproved pharmacological agents that may not be explicitly named.[16] From an International Olympic Committee and Olympic anti-doping perspective, this classification logic means that a supplement’s risk profile cannot be reduced to a finite list of well-known drugs because rule-relevant exposure may include structurally related, novel, or unapproved agents that analytical methods can detect even when consumers or manufacturers are not aware of them.[2, 16]
High-risk product categories
The evidence base supports a pragmatic risk stratification by product type for athlete guidance and for market surveillance priorities, because contamination has been reported most frequently in pre-workout, weight-loss, and muscle-building products in syntheses of empirical testing.[1] The same risk stratification is consistent with FDA warning-letter analyses noting that adulterated products are commonly marketed for sexual enhancement, weight loss, or muscle building, aligning the anti-doping “high-risk supplement” archetype with broader post-market enforcement signals in consumer health regulation.[8]
Contamination Pathways in Manufacturing
Understanding how undeclared substances enter supplements is essential because, under Olympic anti-doping strict liability, athletes are responsible for what is found in body fluids irrespective of origin, which elevates the importance of preventing trace-level carryover and intentional adulteration at the source.[5] The literature distinguishes at least two broad pathways that are relevant to manufacturers, regulators, and anti-doping educators: unintended contamination during manufacturing and deliberate mislabelling through intentional addition of performance-enhancing compounds.[5]
The first pathway—contamination during manufacturing—is described as occurring when the same machines are used to produce non-hormonal and hormonal supplements, leading to unintentional mixing of a product with a very small amount of a banned substance.[5] This mechanism is particularly salient for Olympic anti-doping because analytical methods in sports drug testing are designed to detect very low concentrations, and for many prohibited agents any detected amount constitutes an adverse analytical finding (AAF), making “very small amounts” potentially outcome-determinative for athlete sanctions.[11]
The second pathway—mislabelling—reflects intentional addition of small amounts of performance-enhancing steroid or stimulant compounds to boost effectiveness of a product, which directly creates a label–content gap and can raise both health risks and legal exposure for consumers and athletes.[3, 5] This pathway is consistent with evidence from FDA warning-letter analyses where unapproved drug ingredients were frequently not declared on the label, illustrating that deliberate or negligent non-disclosure is a recurring feature of the adulterated supplement landscape.[8]
Although the evidence quoted here is framed around shared equipment and intentional spiking, the practical implication is that manufacturing controls must explicitly address both cross-contamination and deliberate adulteration if the goal is to reduce undeclared prohibited substances in finished products.[5] In regulatory and quality systems terms, this points towards robust GMP implementation designed to ensure that final products do not include the wrong ingredients or contaminants, and to minimise the risk of unsafe or illegal products reaching the marketplace.[12]
Analytical Detection Methods
Across the supplement-contamination literature relevant to Olympic anti-doping, analytical strategies rely predominantly on chromatographic separation coupled to mass spectrometry because these platforms offer the specificity and sensitivity needed for conclusive interpretation of suspected contamination scenarios.[11] A review of methods reports that liquid chromatography–mass spectrometry (LC-MS) is the most widely used analytical method, followed by gas chromatography–mass spectrometry (GC-MS), and that LC-MS is described as a gold standard due to high sensitivity and the ability to characterise unknown chemical structures without prior reference standards.[2] Method inventories similarly note that LC-MS emerged as the most widely utilised approach (reported as in one synthesis), reinforcing its central role in both screening and confirmatory workflows applicable to Olympic anti-doping and to supplement batch-release testing.[1]
Laboratory workflows typically include matrix-appropriate sample preparation steps followed by instrumental analysis, reflecting the complexity of supplement matrices such as powders, tablets, fluids, and capsules.[4] One described GC-MS workflow includes homogenisation, extraction, derivatisation, and analysis by GC-MS, illustrating a classical approach for analytes where derivatisation improves volatility or chromatographic behaviour.[4] In a national market-surveillance example, 93 supplements were collected for analysis and primarily screened with GC-MS at a medicines agency laboratory, demonstrating how routine enforcement-style testing can align with anti-doping relevant substance detection workflows.[3]
Sensitivity targets are crucial because trace-level contamination can still yield AAFs in routine doping controls, and analytical systems in sports drug testing have excellent detection limits designed for such scenarios.[11] One analysis reports limits of detection ranging from 5 to 100 ng/g, explicitly noting that these limits allow determination of trace contaminations in “nonhormonal” nutritional supplements, which is directly relevant to the plausibility that cross-contamination or low-dose adulteration could trigger Olympic anti-doping consequences.[17] Another method applied to dietary supplement samples () reported LOD and LOQ values of <5 μg L and <10 μg L, respectively, and observed a total detection rate of 13.5% (27/200), showing that multi-sample online-market screening can yield substantial positivity rates when using validated analytical methods.[18]
GC-MS remains indispensable for certain compound classes and is frequently specified with detailed instrumental parameters in the contamination literature.[19] For example, GC-MS analyses have been described as performed on an Agilent 6890 GC system coupled to an Agilent 5973 mass selective detector with electron ionisation at 70 eV, reflecting established anti-doping-adjacent instrumental configurations used to detect prohibited agents and analogues.[19] Designer-steroid investigations similarly report GC-MS analysis in SCAN mode after methanolic extraction and derivatisation, and confirmation may be performed according to WADA criteria, explicitly connecting analytical confirmation standards to anti-doping governance requirements.[19, 20]
High-resolution mass spectrometry (HRMS) supports broad-scope screening for multiple classes of substances relevant to both WADA-prohibited categories and broader pharmacological adulterants.[21] One validated LC-Orbitrap-HRMS method after solid phase extraction was optimised to detect anabolic agents, beta-agonists, hormone and metabolic modulators, diuretics, and stimulants, closely matching major WADA Prohibited List classes and therefore reinforcing the translational link between Olympic anti-doping laboratories and consumer-product testing.[16, 21] A UHPLC-QTOF-MS approach described use of AIF mode to provide fragment ion information enabling qualitative and quantitative results in a single run, while data-processing strategies such as extracting key and assistance ions and applying Jaccard similarity score thresholds were described as tools to reduce false-positive and false-negative errors in library-based identification workflows.[22]
Cost and throughput considerations can motivate multi-tier strategies that use lower-cost screening modalities prior to confirmatory MS-based testing, especially for manufacturers or regulators needing to triage large numbers of products.[23] For instance, UV detection has been described as inexpensive and widely applicable, and mobile phase selection can preserve compatibility with LC-MS when additional identification and confirmation are required, illustrating a pragmatic pipeline from initial screening to definitive confirmation.[23]
Summary table of method roles
The table below summarises how major analytical modalities are positioned in the cited evidence, highlighting why chromatographic–mass spectrometric methods dominate Olympic anti-doping relevant workflows while lower-cost screening can support scale-up.[2, 11]
Regulatory Landscape
From the International Olympic Committee standpoint, the persistence of undeclared pharmacologically active substances in dietary supplements is strongly influenced by regulatory architectures that differ from drug regulation and allow products to reach consumers without premarket evaluation commensurate with their potential pharmacological risks.[8, 9] Under DSHEA in the United States, dietary supplements—including nutritional ergogenic aids not intended to diagnose, treat, cure, or prevent disease—do not need to be evaluated by the FDA prior to commercialisation, making market access comparatively permissive relative to pharmaceuticals.[9] This structure is consistent with descriptions that dietary supplements are classified as a category of food and are not subject to the premarket safety and effectiveness testing required for drugs, thereby shifting the system’s center of gravity towards postmarket surveillance and enforcement actions after harms or violations are detected.[8]
Regulatory summaries further characterise supplements and their ingredients as generally presumed safe and emphasise that the FDA lacks authority to require safety and efficacy testing before supplements enter the market, which helps explain why contaminated or adulterated products can persist until detected through surveillance rather than being filtered premarket.[12] In practice, postmarket surveillance is described as relying on adverse event reports, consumer complaints, inspections of supplement firms, and screening of imported products to identify unsafe or adulterated supplements containing unapproved ingredients.[8] This is directly relevant to Olympic anti-doping because strict liability means that an athlete can be sanctioned based on the presence of a prohibited substance even when exposure occurs through ordinary consumer channels operating under a postmarket regulatory posture.[4, 5]
Although DSHEA authorised FDA to promulgate dietary supplement-specific good manufacturing practices (GMP) and established requirements for new dietary ingredients and labelling, the statutory framing also emphasised avoiding “unreasonable regulatory barriers,” and regulatory descriptions note that the FDA often does not take action until something goes wrong under the food-like regulatory approach to supplements.[12] GMPs are described as including testing to ensure quality, confirming absence of contaminants, verifying labelling accuracy, maintaining minimal marketing/packaging standards, monitoring and reporting adverse events, and making records available for FDA inspection, indicating that the intended control framework includes quality systems that could, in principle, reduce undeclared substances if consistently implemented.[24]
Enforcement and compliance constraints, however, appear substantial and plausibly contribute to the persistence of undeclared substances reaching consumer shelves.[25] One report notes that an FDA report published in 2013 revealed 70% of manufacturers were in violation of GMPs, especially regarding finished product verification, and another indicates the FDA has scant resources for dietary supplement oversight, with only 4% of the FDA Center for Food Safety and Nutrition budget dedicated to dietary supplements.[25] Complementary inspection analyses reported that 58% of inspected facilities were cited with observations or violations of cGMP, and that 19% of cited companies failed to set specifications for identity, purity, strength, and composition of the final product, with 16% failing to verify identity of a dietary ingredient through an appropriate test or method, collectively indicating material weaknesses in foundational quality controls that should prevent undeclared substances.[26]
Postmarket enforcement data further illustrate the magnitude of undisclosed pharmacological adulteration detected after products have entered commerce.[8] A quality improvement study analysing FDA warnings (2007–2016) found unapproved pharmaceutical ingredients identified in 776 dietary supplements, commonly marketed for sexual enhancement, weight loss, or muscle building, and noted that in most cases (757/776; 97.6%) these ingredients were not declared on the label, directly reinforcing the central problem of undeclared substances and label–content mismatch relevant to both consumer safety and Olympic anti-doping risk.[8]
Internationally, regulatory structures differ and may create uneven consumer and athlete protection across jurisdictions, with implications for cross-border purchasing and online commerce.[1, 27] In the European Union, stricter oversight has been described under the Food Supplements Directive (2002/46/EC), but regulatory fragmentation across member states is described as resulting in varied enforcement practices, implying that the same product class may encounter different degrees of scrutiny depending on national implementation and enforcement capacity.[27]
6. Clinical and Legal Consequences
The most distinctive clinical–legal feature of supplement contamination in sport is that sanctions under the World Anti-Doping Code are anchored in strict liability rather than proof of intent, which makes undeclared substances in supplements a direct pathway from consumer exposure to disciplinary action in Olympic anti-doping systems.[28] Strict liability is described as the keystone of the World Anti-Doping Code, underpinned by the statement that it is an athlete’s personal duty to ensure no prohibited substance enters the body.[28] Consequently, an athlete can be judged to have committed an ADRV whether the prohibited substance was used intentionally or unintentionally and regardless of negligence or fault, creating a legal environment in which manufacturing contamination and mislabelling can have severe career consequences even when athletes act in good faith.[1, 28]
Mechanistic data illustrate why “trace” contamination can still be sanction-relevant: small amounts of prohibited substances may produce detectable urinary metabolites above thresholds used in anti-doping adjudication.[29] In a controlled evaluation, ingestion of trace amounts of 19-norandrostendione resulted in marked elevation of urinary 19-norandrosterone (19-NA) and 19-noretiocholanolone (19-NE), demonstrating biological plausibility for positive tests from low-level exposures.[29] Under current WADA regulations described in that study, a 2.5 mg dose led to five (20%) subjects who would have tested positive, and a 5.0 mg dose led to 15 (75%) exceeding urinary 19-NA concentrations of 2 ng/mL, indicating that relatively small doses can yield a substantial positivity fraction in controlled settings.[29] Another report contextualised contamination magnitude by stating that adding 2.5 mg 19-norandrostendione to a fluid-based supplement—equivalent to (w/v) contamination—was sufficient to result in a doping violation in some individuals, reinforcing that very low contamination fractions can be outcome-determinative in Olympic anti-doping adjudication.[30]
Case narratives and arbitration outcomes further show how supplement contamination can progress from analytical findings to Olympic-level exclusions and suspensions, even when athletes demonstrate diligence.[25] In the example of swimmer Jessica Hardy, her sample contained clenbuterol (a beta-agonist with anabolic properties on prohibited lists), and she was banned from the Olympic Games and served a one-year suspension despite conscientiousness, illustrating the high stakes of inadvertent exposure through supplements or other products.[25] The sanction was reduced because the Court of Arbitration for Sport found that she exercised sufficient diligence in her investigation of the supplement, highlighting that diligence may mitigate penalties but does not negate strict-liability responsibility for the presence of the prohibited substance.[25, 28]
Population-level anti-doping monitoring data support that supplement-attributed ADRVs are not rare in long-running programmes, and they demonstrate substance-class patterns consistent with the contamination literature.[7] In an 18-year Norwegian programme (2003–2020), in 49 (26%) of 192 analytical ADRV cases the athlete claimed that one or more dietary supplements contained a prohibited substance that resulted in the adverse analytical finding.[7] Evidence supporting a causal relationship between supplement use and the prohibited substance detected was found in 27 of those 49 cases, and the proportion of analytical ADRVs attributed to supplements containing prohibited substances was reported as likely between 14% and 19% of all analytical ADRVs over the period, showing that supplements can plausibly account for a material fraction of positive tests in some settings.[7] Stimulants were described as the most prevalent substance group linked to supplements containing prohibited substances (89%; 24 of 27 cases), and multi-ingredient pre-workout supplements were among the categories most frequently implicated, aligning with prevalence syntheses that identify pre-workout products among the categories most often contaminated.[1, 7]
Clinically, undeclared substances also raise broader safety and public health concerns because consumers may unknowingly ingest pharmacologically active agents, and some identified substances may cause adverse health effects, with legality varying by jurisdiction and enforcement context.[3] Legally, the combination of undeclared ingredients and strict liability means that product defects can translate into sanctions, while the regulatory environment may still permit contaminated products to circulate until detected postmarket, creating a persistent mismatch between consumer-market realities and Olympic anti-doping expectations of substance control.[5, 8]
7. Quality Assurance Solutions
Quality assurance (QA) in this area is driven by an empirically documented gap between product labels and actual chemical composition, which has been characterised as a persistent threat to athlete integrity and public health.[1] The literature stresses the need for more stringent international manufacturing standards and expanded analytical screening protocols, alongside enhanced athlete education, to mitigate the risk of unintentional doping arising from supplement use.[1] Within the Olympic anti-doping ecosystem, QA approaches must therefore combine upstream manufacturing governance with downstream verification mechanisms that are credible under strict liability and responsive to evolving prohibited-substance categories.[5, 31]
One practical recommendation aimed at athletes is to request a quality control certificate from supplement suppliers, with the certificate demonstrating that the product was tested at an independent IOC-accredited laboratory and shown to be free of prohibited substances, thereby linking product selection to verifiable analytical evidence rather than marketing claims.[5] At the same time, guidance explicitly notes that the International Olympic Committee does not endorse any nutritional supplements, reinforcing that selection decisions and risk acceptance remain the responsibility of athletes and their support teams rather than being transferable to IOC endorsement.[5]
Third-party certification programmes are positioned as a structured risk-reduction tool, but their limitations and implementation realities require careful interpretation by athletes, clinicians, brand owners, and regulators.[32, 33] Programmes are described as fee-based and voluntary, and in one example of military commissary shelves only 12% of dietary supplements were independently certified, indicating that certification coverage in the marketplace can be limited and uneven.[32] Certification is also described as batch-specific, meaning that a certified designation applies to a specific production batch and does not extend to other batches, which implies that QA must be operationalised at the lot level if it is to be meaningful for Olympic anti-doping risk management.[34]
The evidence also emphasises that certification does not equate to absolute safety because it is impossible to test for all banned substances, and therefore manufacturers cannot credibly claim a product is “free from all banned substances” solely because it has undergone a certification process.[33] Consistent with this, certification is described as unable to completely eliminate the risk that a dietary supplement is contaminated, although it is reported to have strong evidence of reduced risk, suggesting that certification should be framed as a probabilistic safeguard rather than an unconditional guarantee.[33]
Programme credibility depends on governance features and laboratory competence criteria that align with recognised conformity-assessment standards and with WADA’s evolving prohibited list.[31] Third-party certification programmes are described as typically testing for prohibited substances, heavy metals, and labelling accuracy, and the integrity of the testing process is linked to laboratory compliance with ISO 17065-related expectations for equipment, expertise, processes, and conflict-of-interest controls.[6] More detailed recommendations specify that certifiers should be demonstrably impartial and accredited to ISO 17065, that evaluation should be to the consensus standard ANSI/NSF 173 with a full audit to 21 CFR 111, and that analytical work should be conducted in ISO 17025-accredited laboratories with scope including dietary supplements.[31]
For Olympic anti-doping relevance specifically, a core expectation is that certification programmes test for substances prohibited in sport and use the WADA Prohibited List as the foundation while incorporating new performance-enhancing drugs as they become known.[31] Because the WADA Prohibited List changes at least annually, programmes must continually add substances to their banned-substance screens and use risk-based approaches to ensure common banned substances are not present, and processes should exist to ensure newly discovered doping agents are not present in certified dietary supplements.[31]
Manufacturing quality systems remain a foundational layer even when third-party testing is used, because GMP establish minimum standards for manufacturing, packaging, labelling, and holding to ensure product quality and minimise risks of unsafe or illegal products reaching the marketplace.[12] Following GMP is described as helping ensure that final products do not include wrong ingredients or contaminants and do not suffer from improper packaging or labelling, aligning GMP with prevention of both cross-contamination and mislabelling-related pathways described in the contamination literature.[5, 12] However, inspection data indicating high rates of cGMP observations and frequent failures to set specifications or verify ingredient identity underscore that QA solutions must be evaluated in light of real-world compliance gaps, strengthening the rationale for independent testing and transparent documentation in high-risk contexts such as elite sport.[26]
Named certification programmes and the limits of current evidence
The cited evidence establishes general principles for third-party certification (scope of testing; ISO-accredited laboratories; audits to 21 CFR 111; alignment to the WADA Prohibited List) but does not, within the provided quote set, name specific commercial programmes such as NSF Certified for Sport, Informed Sport, or BSCG.[31] Accordingly, while such programmes are frequently discussed in practice, any programme-specific claims must be grounded in programme documentation and peer-reviewed evaluations beyond the evidence provided here, and the general requirements outlined above provide a standards-based template against which those programmes can be assessed for Olympic anti-doping risk reduction.[31]
Similarly, the provided evidence emphasises manufacturing standards and analytical screening but does not substantiate specific pharmaceutical-grade contract development and manufacturing organisation (CDMO) practices such as nitrogen blanketing, TOTOX control, or alu-alu moisture barrier packaging as contamination-prevention measures for this particular risk domain.[1, 12] These practices may be relevant to product stability and oxidation control, but claims about their impact on undeclared prohibited-substance contamination would require direct evidence not contained in the current quotes, and therefore are not asserted here.[1]
8. Conclusion
The available evidence supports the conclusion that undeclared substances in dietary supplements represent a persistent and measurable problem at the interface of consumer markets and Olympic anti-doping governance.[1, 9] Contamination prevalence estimates in empirical studies (commonly described around 9–15% in syntheses, with some reports of much higher rates in specific study contexts) demonstrate that the problem is not a fringe phenomenon and can affect product categories commonly used by athletes, including pre-workout, weight-loss, and muscle-building products.[1, 3]
The Olympic anti-doping significance is amplified by strict liability under the World Anti-Doping Code, which permits an ADRV finding regardless of intent and places the duty on athletes to avoid prohibited substances entering the body.[28] Mechanistic and controlled-exposure evidence indicates that low-level exposures can elevate urinary metabolites and produce positive tests under WADA regulations, meaning that even small contamination fractions (e.g., (w/v) in a reported scenario) can be sufficient to yield doping violations in some individuals.[29, 30] Case and monitoring evidence further show that supplement-linked scenarios can lead to Olympic exclusion and suspension and may account for a substantial fraction of analytical ADRVs in long-running anti-doping programmes, with stimulants frequently implicated and pre-workout products appearing as common sources in attributed cases.[7, 25]
From a public health and regulatory perspective, the persistence of undeclared substances is plausibly sustained by market-access structures in which supplements are not subject to drug-like premarket safety and effectiveness testing and in which postmarket surveillance and enforcement detect, rather than prevent, many violations.[8, 12] Postmarket enforcement analyses identifying large numbers of supplements containing unapproved pharmaceutical ingredients that are usually not declared on labels reinforce that label–content mismatch is a systemic issue rather than a collection of isolated events.[8]
Risk reduction is therefore best approached as a layered QA strategy: rigorous GMP implementation to prevent contamination and mislabelling, independent and appropriately accredited laboratory testing, and third-party certification programmes designed to test for prohibited substances and aligned to the annually evolving WADA Prohibited List while acknowledging that certification cannot eliminate all risk because it is impossible to test for all banned substances.[12, 31, 33] Within this framework, the International Olympic Committee’s position that it does not endorse supplements underscores that athletes and organisations must rely on evidence-based QA processes rather than marketing cues, and that Olympic anti-doping credibility depends in part on translating laboratory-grade detection and quality systems into the consumer-supplement supply chain.[1, 5, 11]
